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Abstract: Androgen deficiency in males has traditionally been predominantly limited to older men
aged 50+ years. However, little is known of the correlation between hormonal disruption, stress,
and sleep in college-aged males. This cross-sectional study investigates lifestyle behavior patterns in
young men and a screening for potential androgen deficiency. A survey of 409 male students, as part
of a larger USDA-funded GetFruved study, was analyzed for this subproject. Survey instruments
used include the Androgen Deficiency in the Aging Male Questionnaire (ADAM) to assess for
inadequate ADAM scores, the Perceived Stress Scale to measure stress levels and the Pittsburgh Sleep
Quality Index to evaluate sleep quality. In total, 144 male participants (35%) met criteria for potential
androgen deficiency defined by the ADAM questionnaire. Correlation was found between having a
positive ADAM score and both increased stress levels (p < 0.001) and poor sleep quality (p < 0.001),
with stress displaying the strongest effect (p < 0.001 vs p = 0.124). An increased prevalence of having
a positive ADAM score versus established norms for this age group was also noted. These findings
highlight the need for investigation of endocrine disruptions in young men.
Keywords: androgen deficiency; ADAM score; low testosterone; young adult males; stress; sleep
1. Introduction
It is known that male androgen deficiency is more predominant among older-men,
with prevalence rates of 34% for men in their 60s, 91% for men in their 80s, and less than 5% in males
aged 20–29 [1]. Note that, due to testosterone being the primary male androgen hormone, the term
male androgen deficiency, hypogonadism, male low testosterone, and male testosterone deficiency are
used interchangeably in the literature. Additionally, hormone-based treatment is typically referred to
as testosterone treatment for all of these conditions. However, the widespread rise of obesity, and its
accompanying host of co-morbidities, including type 2 diabetes (T2DM), cardiovascular disease (CVD),
and metabolic syndrome (MetS), is changing long-held assumptions about hormonal disruptions. Male
hypogonadism has been found to positively correlate with all three of these co-morbid conditions [2–6].
Although prevalence rates are difficult to assess for individuals with CVD and MetS, in males
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with T2DM, hypogonadism prevalence is estimated to be 33–50% [7]. These trends are particularly
concerning in younger demographics which have experienced significant increases in obesity rates in
the past fifteen years. The Centers for Disease Control (CDC) reported that prevalence of obesity among
American teenagers almost doubled from 2001 to 2015, going from 10.5% to 20% [8]. Additionally,
nearly a third of young adults in the U.S. were considered obese in 2015 [8]. Interestingly, although
treatment of hypogonadism remains challenging [9], medical management of androgen deficiency in
males has displayed encouraging results. In obese men with low testosterone, testosterone replacement
resulted in improved body composition and reduced waist circumference, leading to sustained weight
loss and reduced body mass index (BMI) [10]. In male patients with androgen deficiency and T2DM,
a disorder itself with a high prevalence of male hypogonadism [11,12], similar treatment not only
yielded decreased subcutaneous fat and increased lean mass, it also improved insulin sensitivity [13].
In addition to specific medical diagnoses, certain lifestyle factors with well-established hormonal
components can significantly affect health. Sleep and stress have been found to both be mediated by
hormones and to have the capacity to alter normal endocrine function [14,15]. Indeed, male testosterone
production appears to be linked to sleep cycles, including REM sleep [16]. Furthermore, young adults
frequently experience poor sleep, with only approximately a third of college students reporting good
sleep quality using the Pittsburgh Sleep Quality Index (PSQI) scale and 29.4% reporting getting
the ≥8 h of sleep recommended for this population [17]. Emerging evidence suggests that reduced
sleep is a potential risk factor for obesity [18]. Stress (personal and academic) has been shown to
significantly affect sleep quality in young adults [17]. Additionally, male teenagers with decreased
stress resilience, or reduced ability to successfully cope with an issue, have been shown to be at
increased risk of developing T2DM in adulthood, even when accounting for traditional risk factors
such as BMI and family history [19]. Endocrine disruptions can result in a variety of physiological,
cognitive and emotional conditions, which can each bring their own negative contribution to overall
health, resulting in a snowballing effect damaging long-term quality of life and leading to increased
healthcare costs.
The relationships among having a potential androgen deficiency, sleep, and stress in young adult
males are unknown. This study investigated 409 male college students enrolled in the USDA-funded
GetFruved study to examine if potential androgen deficiency, sleep, and stress are related via
self-reported questionnaires.
2. Materials and Methods
Over 1200 college students across eight U.S. universities were surveyed as a part of a
USDA-funded GetFruved study, a project aimed at identifying and improving lifestyle behaviors and
environments associated with obesity prevention on university campuses. Male students (n = 409)
were analyzed as a part of this subproject. Approval to use the dataset was granted by the University of
Tennessee Institutional Review Board prior to study implementation. This material is based upon work
that is supported by the National Institute of Food and Agriculture, U.S. Department of Agriculture,
under award number 2014-67001-21851.
The validated survey instrument used included the Androgen Deficiency in the Aging Male
Questionnaire (ADAM) to assess potential androgen deficiency [20,21]. This tool has been utilized
to assess low bioavailable testosterone in older males aged 40–62 years and evaluated the change
of these scores after administration of testosterone to those found to be low [21]. The ADAM tool
was analyzed to have an 88% sensitivity and 60% specificity in capturing those males with lower
testosterone. Specifically, 18 of the 21 men given testosterone treatment found improvement in their
ADAM scores. Authors state the ADAM questionnaire poses an acceptable tool for screening tool for
capturing males with low bioavailable testosterone.
The ADAM questionnaire was scored using the defined instructions listed in Figure 1, with a
positive ADAM score being suggestive of a potential androgen deficiency [21]. A positive score was
indicated as a “yes” answer to Question 1 or 7, or any other three variables. Per the scoring, the ADAM
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tool is then placed into a binary variable of “positive” or “negative”. Note that participants with a
positive ADAM score are henceforth labeled as “ADAM positive”, with their negative counterparts
being referred to as “ADAM negative”.
Additional validated tools to assess these male’s lifestyle traits included Cohen’s 14-item Perceived
Stress Scale (PSS) to measure stress levels [22] and the Pittsburgh Sleep Quality Index (PSQI) to
evaluate sleep quality [23]. Sleep quality was further categorized per PSQI guidelines, with scores of
0–4 indicating good sleep quality and scores ≥5 indicating poor or inadequate sleep quality [23].
Wilcoxon tests were used on nonparametric data to compare means for the following variables:
height, weight, BMI, PSS scores, and PSQI scores. Pearson Chi-Squared test was used to assess
the relationship between ADAM scores and PSQI categories. Logistic Regression Analysis and
Agreement Analysis of the data were conducted to assess the effect of sleep and stress on ADAM
scores. All analyses were completed using JMP [24] and SAS [25] software.
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Figure 1. Androgen Deficiency in the Aging Male Questionnaire (ADAM). This non-invasive screening
tool was administered to all participants to assess androgen deficiency.
3. Results
There were 409 males from eight different states included in analysis (Table 1). Their average
height, weight BMI and waist circumference were 176.06 ± 7.40 cm, 77.43 ± 15.98 kg,
24.90 ± 4.62 kg/m2, and 82.94 ± 10.49 cm respectively (all Wilcoxon analyses non-significant between
ADAM positive and ADAM negative groups; Table 1). The sample was predominantly composed of
individuals identifying their race as 70.2% White, 17.1% Hispanic/Latino, 14.4% Asian, 12.0% Black
only, 8.8% other (including Alaska Native/American Indian, Native Hawaiian/Pacific Islander and
Other) (Table 1).
Overall, males had a PSS of 23.23 ± 7.40 and a PSQI score of 5.72 ± 2.64. Following PSQI
categorization, good sleep quality was reported by 145 (36.16%) participants and poor sleep quality by
256 (63.84%) participants.
There were 144 (35.21%) male subjects that met the criteria for having a potential androgen
deficiency as defined by positive ADAM questionnaire. Height, weight and BMI were not found to be
significantly different between the ADAM positive and ADAM negative participants (Table 2).
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Table 1. Demographics. Race, and state of the overall sample and the ADAM-positive sub-sample.
Demographic
Frequency (%)
Male Sample ADAM Positive Sub-Sample
N = 409 N = 144
Race *
Alaska Native/American Indian 16 (3.91) 5 (3.47)
Asian 59 (14.43) 21 (14.58)
Black/African-American 49 (11.98) 18 (12.50)
Hispanic/Latino 70 (17.11) 21 (14.58)
Native Hawaiian/Pacific Islander 3 (0.73) 1 (0.69)
White 287 (70.17) 100 (69.44)
Other or Choose not to answer 17 (4.16) 8 (5.56)
State
Alabama 23 (5.62) 9 (6.25)
Florida 79 (19.32) 28 (19.44)
Kansas 35 (8.26) 11 (7.64)
Maine 63 (15.40) 14 (9.72)
New York 65 (15.89) 20 (13.89)
South Dakota 15 (3.67) 6 (4.17)
Tennessee 85 (20.78) 33 (22.92)
West Virginia 40 (9.78) 21 (14.58)
Choose not to answer 4 (0.98) 2 (1.39)
* Individuals were able to classify themselves as more than one race (i.e. White and Hispanic/Latino) making the
total percentage of race > 100%.
Table 2. Anthropometrics by ADAM scores. Height, weight, and BMI of the overall sample,
including comparison between positive and negative ADAM scores with no statistically significant
difference noted.
Anthropometric Total Male Sample ADAM SCORES Significance
Positive Negative
Height (cm) 176.06 ± 7.40 175.50 ± 7.23 176.36 ± 7.48 Z = −0.975,p = 0.3293, Wilcoxon
Weight (kg) 77.43 ± 15.98 77.95 ± 16.67 77.15 ± 15.62 Z = 0.323,p = 0.7460, Wilcoxon
BMI (kg/m2) 24.90 ± 4.62 25.20 ± 4.88 24.74 ± 4.48 Z = 0.905,p = 0.3652, Wilcoxon
Waist Circumference (cm) 82.94 ± 10.49 82.46 ± 9.66 83.19 ± 10.92 Z = 0.7542,p = 0.7538, Wilcoxon
Wilcoxon test used on nonparametric height, weight, and BMI in relationship to ADAM positive and negative scores.
Figure 2 showing box plot of PSS among ADAM positive and negative males. Participants with
positive ADAM scores self-reported higher levels of stress (PSS Mean = 26.82 ± 6.91) than participants
with negative ADAM scores (PSS Mean = 21.26 ± 6.91) (Z = 7.194, p < 0.001, Wilcoxon).
Mean PSQI score of the ADAM positive males was 6.68 ± 2.92 versus 5.19 ± 2.31 for the ADAM
negative participants (Z = 5.177, p = 2.3 × 10−7, Wilcoxon). Sleep findings were consistent following
categorization, with poorer sleep quality observed in ADAM positive participants (χ2 (1) = 12.621,
p < 0.001, Pearson Chi-Squared). In ADAM positives, categorized PSQI scores indicated that good
sleep quality was reported by 35 (24.65%) participants and poor sleep quality by 107 (75.35%)
participants. In ADAM negatives, categorized PSQI scores indicated that good sleep quality was
reported by 110 (42.47%) participants and poor sleep quality by 149 (57.53%) participants. Conversely,
ADAM positive subjects represented 42% of the “poor sleepers” but only 24% of the “good sleepers”,
as shown in Figure 3.
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Univariate logistic regression showed statistically significant effects of increased stress (p < 0.001)
and poor sleep (p = 0.0003) on ADA scores. hen modeled together, stress show a stronger effect
than sleep on ADAM scores (χ2 (1) = 36.68, p < 0.001 versus χ2 (1) = 2.37, p = 0.1235 respectiv ly).
4. Discussion
In young adult men, there was a correlation between a positive ADAM score indicating a potential
androgen deficiency and both increased stress levels and poor sleep quality, with stress displaying
the strongest effect on ADAM scores. These findings highlight the potential relationships within the
Healthcare 2018, 6, 121 6 of 8
testosterone–stress–sleep triad in young adult males. The observed connection between hypogonadism
and sleep appears logical given the established role of testosterone in REM sleep cycles [16]. However,
the stronger effect of stress than sleep on ADAM results was interesting and potentially suggestive
of the co-depending nature of stress and sleep. As stress increases, sleep quality is likely to decrease
thereby resulting in sleep as a compounding stressor. Similarly, decreased sleep quality itself may lead
to increased stress levels. As such, true distinction between the two variables remains challenging.
Additionally, the high proportion of male subjects scoring positive on the ADAM questionnaire in
this study appears to indicate a potentially higher prevalence of hypogonadism in young males than
previously reported. Although this sample was a small convenience sample so nationwide prevalence
conclusions cannot be made, an ADAM positivity rate of 35.21% was far greater than the estimated 5%
androgen deficiency rate in young males [1]. One reason for such a large discrepancy could simply
be an underestimation of androgen deficiency prevalence in young men in the current literature.
Indeed, up to date estimates are not readily available and research in the field is primarily relying
on the 2001 Baltimore Longitudinal Study on Aging. Several factors such as public health changes
(i.e., increased obesity) could have reasonably affected the prevalence of androgen deficiency in young
adult males over the past sixteen years. Most universities sampled in this study are located in states
with high obesity rates. Obesity being linked to hormonal disruptions, this may have played a role in
these findings. Indeed, four of the universities represented in this sample come from states ranked in
the top ten for highest obesity rates. Furthermore, all but one institutions are located in a state ranked
in the top 25 for highest obesity rates [26].
Another limitation of this study was the use of a screening questionnaire to assess for a potential
androgen deficiency. By the very nature of its questions, the ADAM questionnaire may lead to a
positive result independently of any androgen changes. For example, a patient’s answer to question
#2 (“Do you have a lack of energy”) could have multiple potential causes, as could responses to
Questions 3, 6, and 10. Furthermore, hormonal dysfunctions can be challenging to pinpoint and even
the best screening tools have margins for errors. The ADAM questionnaire was designed for older
men as androgen deficiency in males has conventionally predominantly been a concern in males
≥50 years old. This particular screening tool was selected as it is the most widely used one clinically
and no young men focused instrument is currently available. However, it has not been specifically
validated in younger males, representing a potential shortcoming of this study. Indeed, the ADAM
questionnaire may not be valid in younger men. Further validation of the test in this population is
strongly warranted. Specifically, when looking into the questions used for the ADAM questionnaire,
potential shortening of the tool could be useful. For example, a question regarding loss of height in
young adult college students may not be useful as muscle mass and structure tend to not deteriorate
in males until after their fifth decade of life that encompasses hormonal deviations and reductions in
exercise [27].
In light of our results and current obesity trends, further investigation, including laboratory
bloodwork to test testosterone, is recommended: (1) to identify any significant changes to the historical
prevalence of androgen deficiency in younger male demographics; and (2) to confirm relationships
among clinically diagnosed androgen deficiency, stress, and sleep using physiological markers.
Note that literature recommends testing of free or bioavailable testosterone as total testosterone
levels can fail to reveal actual testosterone decline, particularly in individuals with milder forms of
hypogonadism [28,29]. Unfortunately, with this multi-state sample of young males, we were unable
to obtain these biochemical data. Indeed, bioavailable testosterone is the most widely used test in
the literature pertaining to the screening for androgen deficiency [21] and should likely be used to
ensure both accuracy and consistency [30]. Future studies should utilize this measure of testosterone,
especially when validating this tool in a younger population. Overall, this study confirms the need
for research to further examine hormonal disruptions and potential health ramifications in young
adult males.
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